Amarin Corp Plc (AMRN)

[Birdbrain Ideas]

It is true that nobody knows what will happen with the Hikma lawsuit, but I do know for certainty that nothing in this case can shut down all the generics, which is what you suggested was a possibility. This case is specific to Hikma. If the other generics had similarly broken the rules, those generics would have been added as defendants to the lawsuit. They were not. So they have nothing to fear. Now that 2006 is around the corner, it's interesting that we'll only be three years away from what would have been the expiration of the patents anyway. If the generics had waited, Amarin would have advertised Vascepa heavily and grown the market so that generics would be eating a slice of a $2 billion cake. Instead, the piggy vulture generics will be nibbling on the crumbs of the marketplace they destroyed. I still don't get their reasoning.